Cargando…

P2 3-year observation study of Plerixafor use in New Zealand

INTRODUCTION: Plerixafor, a novel CXCR4 pathway antagonist, is used to mobilise CD34-positive stem cells for autologous stem cell transplantation to treat haematological malignancy. Data regarding the rates of failure to mobilise and frequency of use of Plerixafor vary widely. METHODS: This retrospe...

Descripción completa

Detalles Bibliográficos
Autores principales: Swinn, Tim, Butler, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8030232/
http://dx.doi.org/10.1093/bjsopen/zrab032.001